
Crisdesalazine
CAS No. 927685-43-6
Crisdesalazine ( AAD-2004 | AAD2004 )
产品货号. M16640 CAS No. 927685-43-6
Crisdesalazine (AAD-2004、AAD2004) 是阿司匹林的衍生物,可抑制微粒体 PGE(2) 合酶-1 (mPGES-1) 活性,以响应 LPS 处理的 BV2 细胞(IC50 为 230 nM)和重组人 mPGES-1 蛋白体外 IC50 为 249 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥3540 | 有现货 |
![]() ![]() |
10MG | ¥5233 | 有现货 |
![]() ![]() |
25MG | ¥7995 | 有现货 |
![]() ![]() |
50MG | ¥11178 | 有现货 |
![]() ![]() |
100MG | ¥15066 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Crisdesalazine
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Crisdesalazine (AAD-2004、AAD2004) 是阿司匹林的衍生物,可抑制微粒体 PGE(2) 合酶-1 (mPGES-1) 活性,以响应 LPS 处理的 BV2 细胞(IC50 为 230 nM)和重组人 mPGES-1 蛋白体外 IC50 为 249 nM。
-
产品描述Crisdesalazine (AAD-2004, AAD2004) is a derivative of aspirin that inhibits microsomal PGE(2) synthase-1 (mPGES-1) activity in response to both LPS-treated BV2 cell with IC50 of 230 nM and recombinant human mPGES-1 protein with IC50 of 249 nM in vitro; blocked free radical production, PGE(2) formation, and microglial activation in the spinal cords in superoxide dismutase 1(G93A) transgenic mouse model of ALS, reduced autophagosome formation, axonopathy, and motor neuron degeneration, improving motor function and increasing life span, which is superior to riluzole or ibuprofen.Alzheimer Disease Phase 1 Clinical.
-
体外实验——
-
体内实验——
-
同义词AAD-2004 | AAD2004
-
通路Immunology/Inflammation
-
靶点PGE synthase
-
受体PGE synthase
-
研究领域Neurological Disease
-
适应症Alzheimer Disease
化学信息
-
CAS Number927685-43-6
-
分子量325.287
-
分子式C16H14F3NO3
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESO=C(O)C1=CC(NCCC2=CC=C(C(F)(F)F)C=C2)=CC=C1O
-
化学全称2-hydroxy-5-({2-[4-(trifluoromethyl)phenyl]ethyl}amino)benzoic acid
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Shin JH, et al. J Neurochem. 2012 Sep;122(5):952-61.
2. Baek IS, et al. Exp Neurobiol. 2013 Mar;22(1):31-7.
产品手册




关联产品
-
HPGDS inhibitor 1
一种有效的、选择性的、口服造血前列腺素 D 合酶 (HPGDS) 抑制剂,酶 IC50 为 0.6 nM。
-
LY3031207
一种新型强效 (IC50=910 ng/mL)、高选择性微粒体前列腺素 E 合酶 1 抑制剂 (mPGES-1),用于治疗未公开的适应症。
-
F092
F092 is a potent inhibitor of hematopoietic prostaglandin D synthetase (H-PGDS), which can be used to study allergic inflammation and vascular-related diseases.